Total and differential white blood cell counts, high-sensitivity C-reactive protein, and cardiovascular risk in non-affective psychoses

Brain, Behavior, and Immunity

Volumn 45, Issue , 2015, Pages 28-35

  Miller, Brian J ^a   Kandhal, Prianka ^a   Rapaport, Mark Hyman ^b   Mellor, Andrew ^c   Buckley, Peter ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c AUGUSTA UNIVERSITY   (United States)

Author keywords

C reactive protein; Cardiovascular disease; Inflammation; Leukocytes; Lymphocytes; Monocytes; Neutrophils; Non affective psychosis; Risk assessment; Schizophrenia

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; CHOLESTEROL; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BRIEF PSYCHOTIC DISORDER; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FRAMINGHAM RISK SCORE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HOSPITAL PATIENT; HUMAN; LEUKOCYTE DIFFERENTIAL COUNT; LIPOPROTEIN BLOOD LEVEL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MONOCYTE; NEUTROPHIL COUNT; OUTPATIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; VITAL SIGN; ADOLESCENT; CASE CONTROL STUDY; CYTOLOGY; IMMUNOLOGY; INFLAMMATION; LEUKOCYTE COUNT; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; NEUTROPHIL; PSYCHOSIS; RISK FACTOR; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTE COUNT; LINEAR MODELS; LOGISTIC MODELS; LYMPHOCYTE COUNT; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MONOCYTES; NEUTROPHILS; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84924187391     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2014.12.005     Document Type: Article

References (48)

1. Consensus development conference on antipsychotic drugs and obesity and diabetes. J. Clin. Psychiatry 2004, 65:267-272. American Diabetes Association, American Psychiatric AssociationAmerican Psychiatric Association, American Association of Clinical EndocrinologistsAmerican Association of Clinical Endocrinologists, American Association of Clinical EndocrinologistsAmerican Association of Clinical Endocrinologists, North American Association for the Study of ObesityNorth American Association for the Study of Obesity.
2. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br. J. Psychiatry 1997, 171:502-508.
3. Choi H., Cho D.H., Shin H.H., Park J.B. Association of high sensitivity C-reactive protein with coronary heart disease prediction, but not with carotid atherosclerosis, in patients with hypertension. Circ. J. 2004, 68:297-303.
4. Conroy R.M., Pyörälä K., Fitzgerald A.P., Sans S., Menotti A., De Backer G., De Bacquer D., Ducimetière P., Jousilahti P., Keil U., Njølstad I., Oganov R.G., Thomsen T., Tunstall-Pedoe H., Tverdal A., Wedel H., Whincup P., Wilhelmsen L., Graham I.M., SCORE project group Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. 2003, 24:987-1003.
5. D'Agostino R.B., Vasan R.S., Pencina M.J., Wolf P.A., Cobain M., Massaro J.M., Kannel W.B. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation 2008, 117:743-753.
6. Devaraj S., Valleggi S., Siegel D., Jialal I. Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome. Curr. Atheroscler. Rep. 2010, 12:110-118.
7. Kaptoge S., Di Angelantonio E., Lowe G., Pepys M.B., Thompson S.G., Collins R., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375:132-140. Emerging Risk Factors Collaboration.
8. Fan X., Liu E.Y., Freudenreich O., Park J.H., Liu D., Wang J., Yi Z., Goff D., Henderson D.C. Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. Schizophr. Res. 2010, 118:211-217.
9. Fennig S., Craig T., Lavelle J., Kovasznay B., Bromet E.J. Best-estimate versus structured interview-based diagnosis in first-admission psychosis. Compr. Psychiatry 1994, 35:341-348.
10. Ford P. An evaluation of the Dartmouth assessment of lifestyle inventory and the leeds dependence questionnaire for use among detained psychiatric inpatients. Addiction 2003, 98:111-118.
11. Galassi A., Reynolds K., He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am. J. Med. 2006, 119:812-819.
12. Goff D.C., Sullivan L.M., McEvoy J.P., Meyer J.M., Nasrallah H.A., Daumit G.L., Lamberti S., D'Agostino R.B., Stroup T.S., Davis S., Lieberman J.A. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr. Res. 2005, 80:45-53.
13. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith S.C., Spertus J.A., Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752. American Heart Association, National Heart, Lung, and Blood InstituteNational Heart, Lung, and Blood Institute.
14. Harris E.C., Barraclough B. Excess mortality of mental disorder. Br. J. Psychiatry 1998, 173:11-53.
15. Hollingshead A.B., Redlich F.C. Social Class and Mental Illness 1958, 387-397. Wiley, New York.
16. Hsu P.C., Nwulia E., Sawa A. Using bioinformatic tools. Am. J. Psychiatry 2009, 166(8):854. 10.1176/appi.ajp.2009.09060908.
17. Jin H., Folsom D., Sasaki A., Mudaliar S., Henry R., Torres M., Golshan S., Glorioso D.K., Jeste D. Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms. Schizophr. Res. 2011, 125:295-299.
18. Kushner I., Rzewnicki D., Samols D. What does minor elevation of C-reactive protein signify?. Am. J. Med. 2006, 119:e17-28.
19. Lemieux I., Lamarche B., Couillard C., Pascot A., Cantin B., Bergeron J., Dagenais G.R., Després J.P. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec cardiovascular study. Arch. Intern. Med. 2001, 161:2685-2692.
20. Lichtermann D., Karbe E., Maier W. The genetic epidemiology of schizophrenia and of schizophrenia spectrum disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2000, 250:304-310.
21. Madjid M., Awan I., Willerson J.T., Casscells S.W. Leukocyte count and coronary heart disease. Implications for risk assessment. J. Am. Coll. Cardiol. 2004, 44:1946-1956.
22. McCreadie R.G., Scottish Schizophrenia Lifestyle Group Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br. J. Psychiatry 2003, 183:534-539.
23. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., Meltzer H.Y., Hsiao J., Scott Stroup T., Lieberman J.A. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 2005, 80m:19-32.
24. Miller B.J., Paschall C.B., Svendsen D.P. Mortality and medical comorbidity among patients with serious mental illness. Psychiatr. Serv. 2006, 57:1482-1487.
25. Miller B., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70:663-671.
26. Miller B., Gassama B., Sebastian D., Buckley P., Mellor A. Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2013, 73:993-999.
27. Miller B., Mellor A., Buckley P. Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses. Brain Behav. Immun. 2013, 31:82-89.
28. Miller B.J., Culpepper N., Rapaport M.H. C-reactive protein in schizophrenia: a review and meta-analysis. Clin. Schizophr. Relat. Psychoses 2014, 7:223-230.
29. Mitchell A.J., Delaffon V., Vancampfort D., Correll C.U., De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol. Med. 2012, 42:125-147.
30. Mitchell A.J., Vancampfort D., Sweers K., van Winkel R., Yu W., De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophr. Bull. 2013, 39(2):306-318. 10.1093/schbul/sbr148.
31. Nurjono M., Tay Y.H., Lee J. The relationship between serum brain-derived neurotrophic factor (BDNF) and cardiometabolic indices in schizophrenia. Schizophr. Res. 2014, 10.1016/j.schres.2014.05.024.
32. Orakzai S.H., Orakzai R.H., Nasir K., Carvalho J.A., Blumenthal R.S., Santos R.D. Relationship between white blood cell count and Framingham risk score in asymptomatic men. Arch. Med. Res. 2007, 38:386-391.
33. Park C.S., Ihm S.H., Yoo K.D., Kim D.B., Lee J.M., Kim H.Y., Chung W.S., Seung K.B., Kim J.H. Relation between C-reactive protein, homocysteine levels, fibrinogen, and lipoprotein levels and leukocyte and platelet counts, and 10-year risk for cardiovascular disease among healthy adults in the USA. Am. J. Cardiol. 2010, 105:1284-1288.
34. Ratliff J.C., Palmese L.B., Reutenauer E.L., Srihari V.H., Tek C. Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness. Psychosomatics 2013, 54:67-73.
35. Rienstra M., Sun J.X., Magnani J.W., Sinner M.F., Lubitz S.A., Sullivan L.M., Ellinor P.T., Benjamin E.J. White blood cell count and risk of incident atrial fibrillation (from the Framingham heart study). Am. J. Cardiol. 2012, 109:533-537.
36. Saha S., Chant D., McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch. Gen. Psychiatry 2007, 64:1123-1131.
37. Said M.A., Sulaiman A.H., Habil M.H., Das S., Bakar A.K., Yusoff R.M., Loo T.H., Bakar S.A. Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in Malaysia. Singapore Med. J. 2012, 53:801-807.
38. Sicras-Mainar A., Rejas-Gutiérrez J., Navarro-Artieda R., Blanca-Tamayo M. C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice. Eur. Psychiatry 2013, 28:161-167.
39. Spencer C.G., Felmeden D.C., Blann A.D., Lip G.Y. Haemorheological, platelet and endothelial indices in relation to global measures of cardiovascular risk in hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. J. Intern. Med. 2007, 261:82-90.
40. Tamminga C.A., Ivleva E.I., Keshavan M.S., Pearlson G.D., Clementz B.A., Witte B., Morris D.W., Bishop J., Thaker G.K., Sweeney J.A. Clinical phenotypes of psychosis in the bipolar-schizophrenia network on intermediate phenotypes (B-SNIP). Am. J. Psychiatry 2013, 170:1263-1274.
41. Tay Y.H., Nurjono M., Lee J. Increased Framingham 10-year CVD risk in Chinese patients with schizophrenia. Schizophr. Res. 2013, 147:187-192.
42. Waterhouse D.F., Cahill R.A., Sheehan F., McCreery C. Prediction of calculated future cardiovascular disease by monocyte count in an asymptomatic population. Vasc. Health Risk Manag. 2008, 4:177-187.
43. Wheeler J.G., Mussolino M.E., Gillum R.F., Danesh J. Associations between differential leucocyte count and incident coronary heart disease: 1764 incident cases from seven prospective studies of 30,374 individuals. Eur. Heart J. 2004, 25:1287-1292.
44. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
45. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64:663-667.
46. Woods SW, 2011. Chlorpromazine Equivalent Doses for Atypical Antipsychotics: An Update 2003-2010. http://%20scottwilliamwoods.com/equivalencesupdate.php.
47. Wysokiński A., Kowman M., Kłoszewska I. The prevalence of metabolic syndrome and Framingham cardiovascular risk scores in adult inpatients taking antipsychotics - a retrospective medical records review. Psychiatr. Danub. 2012, 24:314-322.
48. Yazici M.K., Anil Yağcioğlu A.E., Ertuğrul A., Eni N., Karahan S., Karaağaoğlu E., Tokgözoğlu S.L. The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey. Eur. Arch. Psychiatry Clin. Neurosci. 2011, 261:69-78.